• Product NameVX-680 (Tozasertib, MK-0457)
• Brief DescriptionInhibitors
• Purification99.59%
• Biological ActivityVX-680 (Tozasertib, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.
• Target NameAurora Kinase inhibitor; Bcr-Abl inhibitor; FLT inhibitor
• CAS No. 639089-54-6
• Calculated MW 464.59
• Formulation C23H28N8OS
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1CCN(CC1)C1=CC(NC2=NNC(C)=C2)=NC(SC2=CC=C(NC(=O)C3CC3)C=C2)=N1
  Pathways:Cell Cycle/Checkpoint; Angiogenesis; Chromatin/Epigenetic; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors
  Receptor:Aurora A; Aurora B; Aurora C; Bcr-Abl; FLT3
  Boling pt:
  Melting pt:
  Solubility:DMSO: 93 mg/mL (200.17 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Harrington EA, et al. Nat Med. 2004, 10(3), 262-267.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting